Kimiaki Utsugisawa Selected Research

Kimiaki Utsugisawa Research Topics

Disease

31	Myasthenia Gravis 05/2021 - 01/2002
9	Thymoma (Thymic Carcinoma) 01/2021 - 08/2007
4	Thymus Hyperplasia 01/2018 - 01/2003
3	Autoimmune Diseases (Autoimmune Disease) 01/2017 - 07/2011
3	Myocarditis (Carditis) 09/2013 - 08/2007
3	Hypoxia (Hypoxemia) 04/2005 - 05/2002
2	Muscle Weakness 05/2021 - 01/2017
2	Myositis (Idiopathic Inflammatory Myopathies) 11/2009 - 08/2007
2	Guillain-Barre Syndrome 09/2006 - 01/2003
1	Meningococcal Infections 01/2019
1	Respiratory Tract Infections (Respiratory Tract Infection) 12/2017
1	Meningococcal Meningitis 12/2017
1	Thymus Neoplasms (Thymus Neoplasm) 12/2017
1	Headache (Headaches) 12/2017
1	Osteoporotic Fractures 01/2015
1	Osteoporosis 01/2015
1	Heart Diseases (Heart Disease) 09/2013
1	Taste Disorders (Taste Disorder) 09/2013
1	Pure Red-Cell Aplasia 09/2013
1	Isaacs Syndrome (Neuromyotonia) 09/2013
1	Limbic Encephalitis (Paraneoplastic Limbic Encephalitis) 09/2013
1	Alopecia Areata 09/2013
1	Hypertension (High Blood Pressure) 01/2012
1	Blepharoptosis (Ptosis, Eyelid) 07/2011
1	Rhabdomyosarcoma 08/2007
1	Hyperplasia 07/2007
1	Hypesthesia (Numbness) 09/2006
1	Herpes Zoster 09/2006
1	Chronic Hepatitis C 06/2005
1	Muscular Diseases (Myopathy) 06/2005
1	Hypothyroidism 06/2005
1	Hepatitis A (Hepatitis, Infectious) 01/2003
1	Pheochromocytoma 05/2002

Drug/Important Bio-Agent (IBA)

13	Cholinergic ReceptorsIBA 05/2021 - 01/2003
9	AutoantibodiesIBA 05/2021 - 08/2007
7	AntibodiesIBA 01/2018 - 01/2003
6	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018 - 01/2011
5	eculizumab FDA Link 01/2021 - 12/2017
5	Prednisolone (Predate)FDA LinkGeneric 01/2018 - 01/2005
4	Intravenous Immunoglobulins (IVIG)FDA Link 01/2021 - 09/2006
3	glucose-mannose-glucoseIBA 05/2021 - 01/2019
3	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 09/2013 - 11/2009
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2012 - 01/2010
3	Calcineurin InhibitorsIBA 01/2012 - 02/2010
3	Tacrolimus (Prograf)FDA LinkGeneric 02/2010 - 02/2003
2	Complement System Proteins (Complement)IBA 01/2021 - 12/2017
2	SteroidsIBA 01/2020 - 01/2010
2	Complement Inactivating AgentsIBA 12/2019 - 12/2017
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2017 - 09/2012
2	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 01/2011 - 11/2009
2	ConnectinIBA 01/2011 - 11/2009
2	Methylprednisolone FDA LinkGeneric 01/2011 - 01/2002
2	phytobacteriomycin (PBM)IBA 02/2003 - 01/2003
2	PhytohemagglutininsIBA 02/2003 - 01/2003
2	Interleukin-2 (IL2)IBA 02/2003 - 01/2003
1	zilucoplanIBA 05/2021
1	Complement C5 (Complement 5)IBA 05/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	Immunoglobulin Fc FragmentsIBA 01/2021
1	margatoxinIBA 09/2019
1	Rituximab (Mabthera)FDA Link 12/2017
1	myasthenia gravis anti-skeletal muscle antibody (ASMA)IBA 11/2016
1	GlucocorticoidsIBA 01/2015
1	AutoantigensIBA 09/2013
1	Immunologic Factors (Immunomodulators)IBA 05/2013
1	Indicators and Reagents (Reagents)IBA 09/2012
1	CreatinineIBA 01/2012
1	glucose-regulated proteinsIBA 08/2011
1	Naphazoline (All Clear)FDA LinkGeneric 07/2011
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 07/2011
1	EpitopesIBA 01/2011
1	Muscle Proteins (Muscle Protein)IBA 01/2011
1	2-methylphenyl cinnamateIBA 01/2010
1	SulfurIBA 08/2007
1	AntigensIBA 07/2007
1	Protein Kinase CIBA 07/2007
1	Protein Kinase C-thetaIBA 07/2007
1	Interferon-alpha (Interferon Alfa)IBA 06/2005
1	thyrotropin-binding inhibitory immunoglobulinIBA 06/2005
1	Thyroid HormonesIBA 06/2005
1	Angiotensin IIIBA 04/2005
1	HLA-DR Antigens (HLA-DR)IBA 05/2003
1	Sulfoglycosphingolipids (Sulfatides)IBA 01/2003
1	Neuroprotective AgentsIBA 11/2002
1	alpha7 Nicotinic Acetylcholine ReceptorIBA 05/2002
1	Nicotine FDA Link 05/2002

Therapy/Procedure

9	Therapeutics 01/2021 - 01/2002
6	Thymectomy 09/2019 - 01/2003
4	Activities of Daily Living (ADL) 01/2021 - 12/2017
2	Plasmapheresis 01/2021 - 01/2011
1	Plasma Exchange 12/2017
1	Adjuvant Radiotherapy 05/2013
1	Immunomodulation 11/2009
1	Aftercare (After-Treatment) 01/2005